According to filings with the U.S. Securities and Exchange Commission, Treeline Biosciences is raising up to $421,779,808.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Joshua Bilenker played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Treeline Biosciences
We aspire to build transformative precision medicines for patients with cancer and other serious conditions. Last year, we provided a founders letter that told a story. 15 months into the Treeline journey, we find ourselves in between story and numbers and graphs. While weve made significant progress in building the pipeline we envisioned at company formation, we are a team that wants our data to do the talking. We are excited for the day when we provide scientific disclosure that has clear implications for patients with cancer and other serious diseases. That day is not today. Nevertheless, a new and exciting financing deserves mention.

To learn more about Treeline Biosciences, visit http://www.treeline.bio/
Treeline Biosciences Linkedin Page: https://www.linkedin.com/company/treeline-biosciences/

Contact:
Joshua Bilenker, Chief Executive Officer
857-228-0050
https://www.linkedin.com/in/josh-bilenker-58655b14/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.